In addition, antagonists or neutralizing antibodies targeting some of the DAMPs (HMGB1 and S100A8/A9) or PRR (P2X7R) could protect to a certain extent against multiple etiologically induced AKI, which in turn highlights the great potential of DAMPs in clinical therapy. The gene discussed is S100A8; the disease is acute kidney injury.